{"nctId":"NCT01331681","briefTitle":"Intravitreal Aflibercept Injection in Vision Impairment Due to DME","startDateStruct":{"date":"2011-05-09","type":"ACTUAL"},"conditions":["Diabetes Mellitus","Macular Edema"],"count":406,"armGroups":[{"label":"Intravitreal Aflibercept Injection 2Q4","type":"EXPERIMENTAL","interventionNames":["Biological: VEGF Trap-Eye (BAY86-5321)"]},{"label":"Intravitreal Aflibercept Injection 2Q8","type":"EXPERIMENTAL","interventionNames":["Biological: VEGF Trap-Eye (BAY86-5321)"]},{"label":"Macular Laser Photocoagulation (Control)","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Macular Laser Photocoagulation (Control)"]}],"interventions":[{"name":"VEGF Trap-Eye (BAY86-5321)","otherNames":[]},{"name":"VEGF Trap-Eye (BAY86-5321)","otherNames":[]},{"name":"Macular Laser Photocoagulation (Control)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults ≥ 18 years with type 1 or 2 diabetes mellitus\n* Subjects with DME secondary to diabetes mellitus involving the center of the macula in the study eye\n* Decrease in vision determined to be primarily the result of DME in the study eye\n* BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye\n\nExclusion Criteria:\n\n* Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day 1\n* More than 2 previous macular laser treatments in the study eye\n* Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of Day 1\n* Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, bevacizumab, ranibizumab etc.) within 90 days of Day 1\n* Active proliferative diabetic retinopathy (PDR) in the study eye, with the exception of inactive, regressed PDR\n* Uncontrolled diabetes mellitus, as defined by HbA1c \\> 12%\n* Only 1 functional eye even if that eye is otherwise eligible for the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)","description":"Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"9.55"},{"groupId":"OG001","value":"10.7","spread":"9.32"},{"groupId":"OG002","value":"1.2","spread":"10.65"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF","description":"Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":null},{"groupId":"OG001","value":"53.3","spread":null},{"groupId":"OG002","value":"25.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF","description":"Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF","description":"Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"27.7","spread":null},{"groupId":"OG002","value":"7.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-195.0","spread":"146.59"},{"groupId":"OG001","value":"-192.4","spread":"149.89"},{"groupId":"OG002","value":"-66.2","spread":"138.99"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF","description":"The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.73","spread":"18.932"},{"groupId":"OG001","value":"5.29","spread":"19.058"},{"groupId":"OG002","value":"3.54","spread":"16.768"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF","description":"The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"16.487"},{"groupId":"OG001","value":"5.32","spread":"18.475"},{"groupId":"OG002","value":"2.26","spread":"15.923"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":63},"commonTop":["Nasopharyngitis","Conjunctival haemorrhage","Visual acuity reduced","Cataract","Diabetic retinal oedema"]}}}